The xGen® AML Cancer Panel v1.0 provides 11,743 individually synthesized and quality controlled xGen Lockdown® Probes to achieve deep enrichment of targets from more than 260 genes associated with the AML disease pathway.
Benefits
- High uniformity with 98% of genomic targets covered at greater than 0.2 x mean coverage
- Detect variations reliably with high reproducibility and increased depth of coverage
- Faster time to result with validated functionality using an IDT optimized 4-hour hybridization protocol
- Highly relevant for AML-related applications due to empirically derived targets
- Fast turnaround via easy online ordering and next day shipping
Features
- Individually synthesized and quality controlled lockdown probes
- 11,743 xGen® Lockdown Probes targeting regions within 260 genes
- Targets defined by whole genome and exome sequencing of 200 AML patients
- Compatible with the IDT optimized xGen 4-hour Capture Protocol
Optimized for Acute Myeloid Leukemia Sequencing Applications
| ASXL1 |
FAM154B |
IDH2 |
KDR |
NPM1 |
PRAMEF2 |
| C17orf97 |
FAM47A |
JAK1 |
KIT |
NRAS |
PTPN11 |
| CBL |
FAM5C |
JAK2 |
KRAS |
NTRK3 |
RUNX1 |
| CEBPA |
FLRT2 |
JAK3 |
LRRC4 |
OR13H1 |
TET2 |
| DNMT3A |
FLT3 |
KCNA4 |
MLL3 |
OR8B12 |
TP53 |
| EGFR |
GJB3 |
KCNK13 |
MYC |
P2RY2 |
TUBA3C |
| EZH2 |
IDH1 |
KDM6A |
NF1 |
PCDHB1 |
WT1 |
TABLE 1. FREQUENTLY RESEARCHED GENES INCLUDED IN THE XGEN® AML CANCER PANEL. The panel does not target every exon in each gene, but targets all regions found to be mutated in the TCGA study. For a complete list of genes, click here.
bio-equip.cn
About IDT
Integrated DNA Technologies (IDT) is a leader in manufacturing and developing products for the research and diagnostics life science market. IDT serves the areas of academic research, biotechnology, and pharmaceutical development. IDT was founded by Dr Joseph Walder in 1987. Since then, its development has been guided by an uncompromising approach to quality, a belief in the value of good service, and a determination to minimize consumer costs.
Serving over 80,000 life sciences researchers, IDT is widely recognized as the industry leader in custom oligonucleotides due to its capabilities in:
Analytical Sophistication—IDT pioneered the use of high throughput quality control (QC) methods and is the only oligonucleotide manufacturer to offer purity guarantees and 100% QC. Every oligonucleotide is analyzed by mass spectrometry and purified oligonucleotides receive further analysis by CE and HPLC.
Design Engineering—IDT maintains an engineering division dedicated to advancing synthesis, processing technology, and automation. An in-house machine shop provides rapid prototyping and custom part design/control.
Customer Support—IDT received over 100,000 calls last year with an average wait time of only 8 seconds.
Reagent and Input Control—IDT receives all solvents in large bulk containers, runs QC on all incoming materials, and performs bulk reagent formulation and functional QC on all reagents.
IDT has over 700 employees serving our worldwide customer base from headquarters in Coralville, Iowa, and facilities in San Diego, California; Leuven, Belgium; and Singapore.
中文
